USPTO serial 79291052
TOXSTA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 27, 2021
- Examiner
- MICHELI, ANGELA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with TOXSTA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Benjamin M. Cantor
Benjamin M. Cantor Cantor Colburn LLP20 Church Street22nd FloorHartford, CT 06103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting sensory organs; pharmaceutical preparations for treating cramps; pharmaceutical preparations for treating muscle; pharmaceutical preparations for treating cerebral palsy; pharmaceutical preparations for treating hyperhidrosis; pharmaceutical agents affecting metabolism; bacteria poisons; Pharmaceutical preparations for treating headache; anaesthetics; pharmaceutical preparations for use in the cosmetic field, namely, medicated cosmetics; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; botulinum toxin for medical use for use in the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; pharmaceutical preparations for the treatment of urogenital organ disorders; Pharmaceutical preparations for urogenital organs; pharmaceutical preparations for plastic surgery; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; veterinary substances and preparations for house pets for injuries and pain, namely, pharmaceuticals containing botulinum toxin; Cardiovascular agents for medical purposes; pharmaceutical preparations for treating neurological disorders; pharmaceutical preparations in the nature of botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives used to treat neurological diseases; Ophthalmic preparations; allergy medications; Chemical preparations for pharmaceutical purposes, namely, for neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; Pharmaceutical agents for epidermis; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; pharmaceutical preparations for skincare in the nature of botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives for medical purposes; pharmaceutical preparations for skin care treatment in the nature of botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives for medical purposes; medicines for human purposes, namely, pharmaceutical preparations for the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; Pharmaceutical preparations for orthopedic purposes; pharmaceutical preparations for treating wrinkles; analgesic preparations; medicines for dental purposes; pharmaceutical preparations for treating pain; pharmaceutical preparation for skin care; medicated preparations for skin treatment; pharmaceutical preparations for respiratory organs; preparations for the treatment of burns; preparations for the treatment of scar | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 27, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 6, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 1, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 13, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 13, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 27, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 27, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 11, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 11, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 11, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 21, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 21, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 21, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 2, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 31, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 8, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 19, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 1, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 1, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 11, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 10, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 3, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 11, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 7, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 6, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |